(Q30986509)

28 June 2017

1 reference

title

Docetaxel for treatment of solid tumours: a systematic review of clinical data (English)

1 reference

28 June 2017

1 reference

1 reference

2

Frank Fossella

1 reference

28 June 2017

Alberto Montero

1

1 reference

PubMed ID

15811618

28 June 2017

Gabriel Hortobagyi

series ordinal

3

1 reference

PubMed ID

15811618

28 June 2017

Vicente Valero

series ordinal

4

1 reference

28 June 2017

1 April 2005

1 reference

Lancet Oncology Commission

28 June 2017

1 reference

28 June 2017

6

1 reference

28 June 2017

4

1 reference

28 June 2017

229-239

1 reference

Promotion of microtubule assembly in vitro by taxol

28 June 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970094-2

7 January 2021

Signal transduction pathways of taxanes-induced apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970094-2

7 January 2021

Chemistry and chemical biology of taxane anticancer agents.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970094-2

7 January 2021

Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970094-2

7 January 2021

Risks and benefits of taxanes in breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970094-2

7 January 2021

A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970094-2

7 January 2021

Docetaxel for patients with paclitaxel-resistant Müllerian carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970094-2

7 January 2021

Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970094-2

7 January 2021

Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970094-2

7 January 2021

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970094-2

7 January 2021

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970094-2

7 January 2021

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970094-2

7 January 2021

Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970094-2

7 January 2021

Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970094-2

7 January 2021

Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970094-2

7 January 2021

Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970094-2

7 January 2021

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970094-2

7 January 2021

Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970094-2

7 January 2021

Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970094-2

7 January 2021

Taxanes and capecitabine in combination: rationale and clinical results

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970094-2

7 January 2021

Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970094-2

7 January 2021

The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970094-2

7 January 2021

A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970094-2

7 January 2021

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970094-2

7 January 2021

Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970094-2

7 January 2021

Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970094-2

7 January 2021

Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: a randomized, multicenter phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970094-2

7 January 2021

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970094-2

7 January 2021

Docetaxel as neoadjuvant therapy for radically treatable stage III non-small-cell lung cancer: a multinational randomised phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970094-2

7 January 2021

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970094-2

7 January 2021

Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970094-2

7 January 2021

Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970094-2

7 January 2021

10.1016/S1470-2045(05)70094-2

Identifiers

DOI

1 reference

28 June 2017

1 reference

PubMed ID

15811618